GSK To Present Lotronex Risk Management “Progress Report” At May 5 Cmte.
This article was originally published in The Pink Sheet Daily
Executive Summary
The meeting comes nearly two years after FDA’s re-approval of the irritable bowel syndrome product. GSK’s risk management program is similar to Roche’s Accutane SMART program, which recently received a committee recommendation for an overhaul.